Orphan Drugs Médunik Signs Supply Deal for Orphan Drugs in Canada

Editor: Dominik Stephan

To provide orphan drugs for the Canadian market, Médunik Canada signed a supply deal with speciality pharma company QOL Medical. Officials state that Médunik aims to build further awareness for rare diseases with this cooperation.

Related Companies

(Picture: Médunik Canada)
(Picture: Médunik Canada)

Blainville, Quebec/Canada – Médunik Canada is becoming the local supplier and distributor of two orphan drugs of QOL Medical, a speciality pharmaceutical company. QOL’s Sucraid (sacrosidase) and Ethamolin (Ethanolamine Oleate).

Sucraid oral solution is an enzyme replacement therapy (ERT) for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), a rare, chronic disease. Sucrase-isomaltase deficiency is usually diagnosed during infancy. There is currently no cure for CSID – The only current therapy is a complete elimination of sucrose from the patients diet. Nevertheles, a diet like this is difficult and does not eliminate some symptoms such as watery diarrhea, abdominal pain and cramps, Médunik says. Sucraid (sacrosidase), which is approved by the FDA in the United States, allows children with CSID to ingest limited amounts of sucrose.

Ethamolin (Ethanolamine Oleate injection, 5%, 2mL ampules) is a mild sclerosing agent indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. Bleeding esophageal varices are a serious complication of liver disease and have poor outcome. Although these diseases are quite rare, their treatment has some difficulties to it.

Awareness for Rare Diseases

“We are very pleased to partner with QOL Medical to help Canadians with rare diseases live a normal life by having access to the proper treatments,“ stated Éric Gervais, Executive Vice-President of Médunik Canada. “We, at Médunik Canada, are also committed to deploy our efforts and resources to provide Canadian patients and their physicians with relevant scientific and clinical information aimed at building awareness and promote better diagnosis of rare diseases.“

Derick Cooper, Chief Operating Officer of QOL Medical, stated that “QOL Medical is excited about their new business relationship with Médunik Canada and look forward to jointly making these life changing medications available to patients in Canada. Our company's mission is to assist in expanding disease awareness to aid physicians with identifying these rare diseases and to assist, directly and with partners like Medunik Canada, in making the proper treatments available to physicians and patients.“